ARCHIVES

Patient Advocacy: FDA, NCI Developing Methods For Naming Survivors To Boards

This article is from The Cancer Letter archive.

Vol. 23 No. 05 | February 7, 1997

Download PDF Visit The Full Archive

Related Articles

Letters To the Editor: Blumenthal Coverage Called “Destructive”

November 14, 1997

NCI’s Richard Kaplan named associate director, National Cancer Research Network of UK.

January 2, 2004

Centers Eligible For Comprehensive Identification Names; Rauscher To Pick Four Now, Two More Later

May 24, 1974

DCT Board Approves $8 Million In Contract Projects For Recompetition

October 31, 1980

NCI Continues Making Improvements In Contract Management

May 22, 1981

In Vote Against Tarceva As Maintenance, ODAC Seeks Stronger Survival Benefit

December 18, 2009